Evidence map›Paper›PMID 37894860›Full record

ArticleInternational journal of molecular sciences2023

Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.

Qiong Wu, Anders E Berglund, Robert J Macaulay, Arnold B Etame

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Qiong WuDepartment of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.ORCID 0000-0001-9712-0647
Anders E BerglundDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.ORCID 0000-0002-0393-3530
Robert J MacaulayDepartment of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.
Arnold B EtameDepartment of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.ORCID 0000-0002-9656-4702
Moffitt Cancer Center · US

Funding

Modulating Glioblastoma Stem Cell Clonal Evolution Towards Therapeutic ResponsivenessR21NS120800 · NINDS · H. LEE MOFFITT CANCER CTR & RES INST · PI ETAME, ARNOLD · 2020 to 2021
$453k
Exploiting Epigenetic Vulnerabilities In Glioblastoma Stem Cells Through ReprogrammingR21CA264635 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI ETAME, ARNOLD · 2022 to 2022
$433k
NCI NIH HHS 1R21CA264635NCI NIH HHS R21 CA264635NINDS NIH HHS 1R21NS120800NINDS NIH HHS R21 NS120800
6 · The paper itself

Abstract

Temozolomide (TMZ) is an important first-line treatment for glioblastoma (GBM), but there are limitations to TMZ response in terms of durability and dependence on the promoter methylation status of the DNA repair gene O

Indexed as

Brain NeoplasmsGlioblastomaAntineoplastic Agents, AlkylatingCell Line, TumorDacarbazineDNA MethylationDNA Modification MethylasesDNA Repair EnzymesEpigenesis, GeneticHumansO(6)-Methylguanine-DNA MethyltransferaseTemozolomideTumor Suppressor ProteinsAntineoplastic Agents, AlkylatingDacarbazineDNA Modification MethylasesDNA Repair EnzymesMGMT protein, humanO(6)-Methylguanine-DNA MethyltransferaseTemozolomideTumor Suppressor Proteins5-AzaGBMglioma stem cellmethylationMGMTTMZTUSC3

Identifiers

PMID37894860
PMCPMC10606804
OpenAlexW4387638658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.